Windtree Therapeutics

Windtree Therapeutics is a global, clinical-stage biopharmaceutical and medical device company headquartered in Warrington, Pennsylvania. The company employs 21 people and generated $11.1 million in revenue. Windtree Therapeutics focuses on developing innovative therapeutics to address critical medical needs in acute care markets. Their portfolio includes four clinical and several pre-clinical programs spanning respiratory, cardiovascular, and oncology disease states. The company's lead clinical programs include AEROSURF®, a unique combination of a medical device and a synthetic, peptide-containing surfactant, designed to treat premature infants with respiratory distress syndrome. They are also developing istaroxime, a novel medication that aims to enhance cardiac function in patients with acute heart failure while minimizing the negative side effects associated with current treatments. Additionally, rostfuroxin, a precision medicine, is being researched to target hypertensive patients with specific genetic profiles, focusing on the resistant hypertension market. For more information, visit www.windtreetx.com.

Windtree Therapeutics is a biopharmaceutical company specializing in the development of oncology and cardiovascular treatments. The company is listed on NASDAQ under the ticker symbol WINT. Windtree Therapeutics aims to address significant unmet medical needs through its diverse pipeline of innovative therapies. The company's headquarters is located at 2600 Kelly Road, Suite 100, Warrington, PA 18976-3622. Windtree Therapeutics operates within the healthcare, pharmaceuticals, and biotechnology industries. Windtree Therapeutics focuses on developing innovative therapies, including Istaroxime and SERCA2a activators. The company's product development efforts are supported by a team of experienced professionals. The company's email addresses include [email protected], [email protected], and [email protected]. Windtree Therapeutics targets the healthcare, pharmaceutical, and biotechnology industries. The company's leadership team includes Jed Latkin as CEO, Eric Curtis as President and Chief Operating Officer, Steve Simonson, M.D., as Senior Vice President and Chief Medical Officer, Jamie McAndrew as SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, and George Cox as Vice President of Technical Operations. Windtree Therapeutics leverages its competitive advantages, including over 25 years of medical practice and pharmaceutical industry clinical trial expertise. The company also benefits from over 20 years of experience in accounting, finance, and biotech. Furthermore, the company has nearly three decades of financial and biotech experience. Windtree Therapeutics is committed to supporting patients in crisis situations and arming healthcare providers with therapies that significantly improve upon current standards of care. The company maintains an unrelenting attention to quality and access to care.